INAB
In8bio Inc
NASDAQ: INAB · HEALTHCARE · BIOTECHNOLOGY
$1.47
-2.65% today
Updated 2026-04-30
Market cap
$15.36M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-4.44
Dividend yield
—
52W range
$1 – $6
Volume
0.1M
In8bio Inc (INAB) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — |
| Cost of revenue | $96000.00 | $96000.00 | $96000.00 | $251000.00 | $1.10M | $2.50M | $2.65M | $2.50M |
| Gross profit | $-96000.00 | $-96000.00 | $-96000.00 | $-251000.00 | $-1.10M | $-2.50M | $-2.65M | $-2.50M |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $581000.00 | $2.36M | $5.38M | $7.35M | $14.06M | $16.83M | $16.96M | $10.21M |
| SG&A | $1.42M | $2.71M | $3.18M | $7.31M | $14.46M | $13.51M | $12.64M | $9.65M |
| Operating income | $-2.00M | $-5.13M | $-8.56M | $-14.65M | $-28.52M | $-30.34M | $-30.44M | $-19.86M |
| Operating margin | — | — | — | — | — | — | — | — |
| EBITDA | $-1.97M | $-5.04M | $-8.47M | $-13.87M | $-27.42M | $-27.51M | $-26.94M | $-17.36M |
| EBITDA margin | — | — | — | — | — | — | — | — |
| EBIT | $-2.07M | $-5.13M | $-8.56M | $-14.65M | $-28.52M | $-30.01M | $-29.60M | $-19.86M |
| Interest expense | $14000.00 | $0.00 | $0.00 | $788000.00 | $1.10M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-2.08M | $-5.13M | $-8.56M | $-14.65M | $-27.42M | $-30.01M | $-30.44M | $-19.44M |
| Net income growth (YoY) | — | -146.7% | -66.7% | -71.2% | -87.1% | -9.4% | -1.4% | +36.1% |
| Profit margin | — | — | — | — | — | — | — | — |